Therapy Areas: Central Nervous System
GenomOncology partners with WeTrials to support CNS cancer clinical trials
11 March 2026 - Precision medicine software company GenomOncology announced on Tuesday that it has partnered with WeTrials, an AI-powered patient engagement and trial enablement platform, to help cent...
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
2 March 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that its Phase III FENhance 1 study in relapsing multiple sclerosis (RMS)...
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
27 February 2026 - Gemma Biotherapeutics (GEMMABio), a US-based clinical-stage global genetic medicines company, announced on Thursday that it has dosed its first parent in the Phase 1/2 CHARISMA clin...
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
20 February 2026 - Biopharmaceutical company Lario Therapeutics announced on Thursday that it has received a total of USD2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's R...
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
28 January 2026 - French medical imaging company Guerbet (Euronext Paris:GBT) announced on Tuesday that it has received approval from the European Commission for a new indication in children from birt...
Insilico Medicine signs co-development collaboration agreement with Hygtia Therapeutics
21 January 2026 - Insilico Medicine (HKEX: 3696), a Hong Kong-based clinical-stage biotechnology company that utilises generative artificial intelligence (AI), announced on Tuesday that it has signed ...